Latest News and Press Releases

Boston, MA, Feb. 23, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. summarized the impact of a series of recent announcements about contracts to provide laboratory services and ExoDx®...

Waltham, MA, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx®...

Waltham, MA, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., today announced that it has entered into a preferred provider network agreement with America’s Choice Provider Network...

Waltham, MA, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. has placed an Early Access version of its commercial Shahky system, which quantitively measures exosomal proteins, at...

Waltham, MA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics announced today that the largest private payor in the Mid-Atlantic region has reached a positive coverage decision for its...

Waltham, MA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics has announced the placement of the world’s first system for exosome specific protein analysis, the Shahky system, within a large...

Waltham, MA, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Expounding upon the very successful regional introduction of the ExoDx Prostate(IntelliScore), or EPI, Exosome Diagnostics is thrilled to announce...

Waltham, MA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., recently published a study in the Journal Annals of Oncology, of EGFR Liquid Biopsy detection in patients with Non-Small...

Boston, MA, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that it has executed an agreement for coverage of its prostate cancer risk assessment test, ExoDx®...

Boston, MA, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that the national Medicare price for its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore),...